Answers are grounded in this paper and cite their sources.
Background: Veno-venous ECMO (VV ECMO) is a life-sustaining technique indicated in the most severe forms of acute respiratory distress syndrome (ARDS). VV ECMO remains associated with significant morbidity and mortality. In this context, the identification of prognostic factors during the first week following ECMO implantation seems of high interest. However, little is known about the prognostic values of the kinetics of clinical and biological parameters in this timeframe. Methods: Observational, retrospective, multicenter study conducted in three centers in France and Belgium. We enrolled patients aged 18 years or older who underwent VV ECMO for severe ARDS between March 2020 and January 2023, with at least one endocan assay within 7 days of VV ECMO implantation. Kinetics of endocan and of a panel of clinical and biological markers were compared between surviving and deceased patients. Results: Forty-nine patients were included in our study among whom 30 patients (61%) were deceased on discharge from intensive care. Compared with patients who died, surviving patients had lower membrane fraction of oxygen at D3, lower fresh gas flow at D7, higher tidal volumes at D1 and D7, higher lung compliance and mechanical power at D7, and lower SOFA score at D7. Compared with deceased patients, survivors had a higher pH and lower endocan concentration on D3, and lower fibrinogen on D3 and D7. Conclusion: One week after initiation of VV ECMO support for severe ARDS, there was a significant decrease in the level of support simultaneously with respiratory and overall improvement in surviving patients. Compared to patients discharged alive from ICU, non-survivors were characterized by lower concentrations of endocan concentration at D3.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: